1.A Butterfly-Shaped Primary Cardiac Lymphoma That Showed Bi-Atrial Involvement.
Jung Sun CHO ; Sung Ho HER ; Mahn Won PARK ; Hyoung Doo KIM ; Ju Yeal BAEK ; Ho Joong YOUN ; Ki Bae SEUNG ; Jae Hyung KIM
Korean Circulation Journal 2012;42(1):46-49
We described here a patient who presented with symptoms of heart failure who was found to have severe bilateral impairment of atrioventricular inflow. Primary cardiac lymphoma (PCL) with extensive involvement of the two atria, pericardium and myocardium is an extremely rare tumor in immunocompetent patients. We report here a case of PCL in an immunocompetent patient with involvement of both atria and the atrial septum. The tumor had a butterfly shape. We could not do surgical excision because of the massive pericardiac invasion. The diagnosis was B-cell lymphoma and this was confirmed by the pericardiac biopsy.
Atrial Septum
;
Biopsy
;
Butterflies
;
Heart Atria
;
Heart Failure
;
Heart Neoplasms
;
Humans
;
Lymphoma
;
Lymphoma, B-Cell
;
Myocardium
;
Pericardium
2.Two Cases of Successful Use of Urokinase in Continuous Ambulatory Peritoneal Dialysis Patients with Relapsing Peritonitis.
Ju Yeal BAEK ; Soek Jun SHIN ; Kyu Re JOO ; Byeung Joo SHIM ; Yu Kyung PARK ; Ji Chan PARK ; Ho Cheol SONG ; Euy Jin CHOI
Korean Journal of Nephrology 2004;23(5):830-835
Peritonitis is a frequent and serious complication in continuous ambulatory peritoneal dialysis (CAPD) patients. Recently, due to educational promotion in general hygiene and development of laboratory technique for bacterial cultures and sensitivity test, proper use of antibiotics, the incidence of CAPD peritonitis has gradually decreased. However, CAPD peritonitis is still one of the most common causes of peritoneal dialysis failure and of removal peritoneal catheter. It has been suggested that the formation of biofilm on the inner surface of peritoneal catheter leads to relapsing peritonitis and removal of the peritoneal catheter in CAPD patients. The biofilm is a kind of protecting coat which consists of fibrin inhibiting the penetration of antibiotics. It surrounds and covers the bacteria, making them to survive from the attack of antibiotics. Therefore thrombolytic therapy, urokinase modifies the structure of biofilm, and helps the antibiotics penetrating the fibrin coat, eventually amplify the bacteriocidal effect. We experienced two cases of successful treatment with urokinase and antibiotics in CAPD peritonitis patients. The combination of thrombolytic agents and antibiotics might be one of the strategies for the treatment of CAPD patients who experienced it frequently.
Anti-Bacterial Agents
;
Bacteria
;
Biofilms
;
Catheters
;
Fibrin
;
Fibrinolytic Agents
;
Humans
;
Hygiene
;
Incidence
;
Peritoneal Dialysis
;
Peritoneal Dialysis, Continuous Ambulatory*
;
Peritonitis*
;
Thrombolytic Therapy
;
Urokinase-Type Plasminogen Activator*
3.A case of reactive airway dysfunction syndrome due to chlorine gas exposure.
Kyoung Young NAMKOONG ; Ju Yeal BAEK ; Hye Suk SON ; Choon Hee CHANG ; Myeong Jin KANG ; Hong Mok LIM ; Yong Keun PARK ; Sang Rok LEE
Journal of Asthma, Allergy and Clinical Immunology 2003;23(4):842-845
The reactive airway dysfunction syndrome (RADS), a subset of irritant-induced asthma, has been described following exposure to various irritant gas. We describe a case of RADS occuring following a single exposure to high levels of chlorine gas in the workplace. No documented pre-existing respiratory illness and atopy was identified. Cough, dyspnea, and wheezing were developed with the single accidental exposure to chlorine gas and methacholine provocation test was positive. He was completely recovered with the treatment of corticosteroid and oxygen therapy.
Angioedema
;
Asthma
;
Cellulitis
;
Chlorine*
;
Cough
;
Dyspnea
;
Eosinophilia
;
Hypereosinophilic Syndrome
;
Methacholine Chloride
;
Oxygen
;
Respiratory Sounds
4.Effects of Combined Therapy with Ezetimibe Plus Simvastatin After Drug-Eluting Stent Implantation in a Porcine Coronary Restenosis Model.
Jung Sun CHO ; Myung Ho JEONG ; Doo Sun SIM ; Young Joon HONG ; Kyung Seob LIM ; Jung Ha KIM ; Hyoung Doo KIM ; Ju Yeal BAEK ; Hee Jeoung YOON ; Sung Ho HER ; Seung Won JIN ; Ju Han KIM ; Youngkeun AHN ; Jeong Gwan CHO ; Jong Chun PARK ; Jung Chaee KANG
Journal of Korean Medical Science 2010;25(5):716-722
The aim of this study was to examine the anti-proliferative and anti-inflammatory effects of ezetimibe/simvastatin (E/S) after drug-eluting stent (DES) implantation in a porcine coronary restenosis model. Pigs were randomized into two groups in which the coronary arteries (23 pigs) had DES. Stents were deployed with oversizing (stent/artery ratio 1.3:1) in porcine coronary arteries. Fifteen pigs were taken 10/20 mg of E/S and eight pigs were not taken E/S. Histopathologic analysis was assessed at 28 days after stenting. In neointima, most inflammatory cells were lymphohistiocytes. Lymphohistiocyte count was not different between two groups (337+/-227 vs. 443+/-366 cells, P=0.292), but neointima area was significantly smaller (1.00+/-0.49 mm2 vs. 1.69+/-0.98 mm2, P=0.021) and percent area stenosis was significantly lower (23.3+/-10% vs. 39+/-19%, P=0.007) in E/S group compared with control group. There were no significant differences in fibrin score (1.99+/-0.79 vs. 1.81+/-0.88, P=0.49), endothelial score (1.75+/-0.66 vs. 1.80+/-0.59, P=0.79), and the percent of endothelium covered lumen (43+/-21% vs. 45+/-21%, P=0.84) between E/S group and control group. Combined therapy with ezetimibe and simvastatin inhibits neointimal hyperplasia, but does not inhibit inflammatory infiltration and arterial healing after DES implantation in a porcine coronary restenosis model.
Animals
;
Anticholesteremic Agents/administration & dosage
;
Azetidines/*administration & dosage
;
Coronary Restenosis/diagnosis/drug therapy/*etiology
;
*Disease Models, Animal
;
Drug Combinations
;
Drug Implants/administration & dosage
;
Drug-Eluting Stents/*adverse effects
;
Female
;
Graft Occlusion, Vascular/diagnosis/*drug therapy/*etiology
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage
;
Simvastatin/*administration & dosage
;
Swine
;
Treatment Outcome
5.Treatment of Pulmonary Hypertension with Percutaneous Stenting of Pulmonary Artery in Fibrosing Mediastinitis.
Yu Kyung PARK ; Joung Ran CHOI ; Woo Sin KIM ; Ju Yeal BAEK ; Kyu Re JOO ; Ji Won AN ; Ji Hoon KIM ; Chul Soo PARK ; Yong Seog OH ; Ho Joong YOUN ; Wook Sung CHUNG ; Soon Jo HONG
Journal of the Korean Society of Echocardiography 2005;13(1):23-27
Fibrosing mediastinitis is a rare benign disorder caused by excessive proliferation of fibrous tissue within the mediastinum. Pulmonary artery stenosis is uncommon complication of fibrosing mediastinitis. We present a case of percutaneous stent deployment in a patient with severe pulmonary artery stenosis causing pulmonary hypertension secondary to fibrosing mediastinitis.
Constriction, Pathologic
;
Humans
;
Hypertension, Pulmonary*
;
Mediastinitis*
;
Mediastinum
;
Pulmonary Artery*
;
Stents*
6.Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor.
Jung Sun CHO ; Sung Ho HER ; Ju Yeal BAEK ; Mahn Won PARK ; Hyoung Doo KIM ; Myung Ho JEONG ; Young keun AHN ; Shung Chull CHAE ; Seung Ho HUR ; Taek Jong HONG ; Young Jo KIM ; In Whan SEONG ; Jei Keon CHAE ; Jay Young RHEW ; In Ho CHAE ; Myeong Chan CHO ; Jang Ho BAE ; Seung Woon RHA ; Chong Jim KIM ; Donghoon CHOI ; Yang Soo JANG ; Junghan YOON ; Wook Sung CHUNG ; Jeong Gwan CHO ; Ki Bae SEUNG ; Seung Jung PARK
Journal of Korean Medical Science 2010;25(11):1601-1608
The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) with or without glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with or without Gp IIb/IIIa inhibitor has not been elucidated. Between October 2005 and July 2007, 2,535 patients with ST elevation acute myocardial infarction (STEMI) undergoing PCI in the Korean Acute Myocardial Infarction Registry (KAMIR) were assigned to either of two groups: a group with Gp IIb/IIIa inhibitor (n=476) or a group without Gp IIb/IIIa inhibitor (n=2,059). These groups were further subdivided according to the use of LMWH with low dose UFH (n=219) or UFH alone (n=257). The primary end points were cardiac death or myocardial infarction during the 30 days after the registration. The primary end point occurred in 4.1% (9/219) of patients managed with LMWH during PCI and Gp IIb/IIIa inhibitor and 10.8% (28/257) of patients managed with UFH and Gp IIb/IIIa inhibitor (odds ratio [OR], 0.290; 95% confidence interval [CI], 0.132-0.634; P=0.006). Thrombolysis In Myocardial Infarction (TIMI) with major bleeding was observed in LMHW and UFH with Gp IIb/IIIa inhibitor (1/219 [0.5%] vs 1/257 [0.4%], P=1.00). For patients with STEMI managed with a primary PCI and Gp IIb/IIIa inhibitor, LMWH is more beneficial than UFH.
Acute Disease
;
Aged
;
Drug Therapy, Combination
;
Female
;
Hemorrhage
;
Heparin/*therapeutic use
;
Heparin, Low-Molecular-Weight/*therapeutic use
;
Humans
;
Male
;
Middle Aged
;
Multivariate Analysis
;
Myocardial Infarction/epidemiology/mortality/*therapy
;
Myocardial Revascularization
;
Odds Ratio
;
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors/metabolism
;
Prognosis
;
Registries